published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] MARIPOSA, 2021 1.43 [0.42; 4.87] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Talaschian, 2021 1.56 [0.34; 7.13] Veiga, 2021 2.70 [0.92; 7.92] 1.04[0.80; 1.37]CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, MARIPOSA, 2021, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 202160%1,432moderatenot evaluable deathsdetailed resultsCORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12] Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Talaschian, 2021 1.25 [0.30; 5.14] Veiga, 2021 2.70 [0.92; 7.92] 0.93[0.75; 1.15]CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, REMAP-CAP (tocilizumab), 2021, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 2021910%2,730moderatenot evaluable deaths (time to event analysis only)detailed resultsCOVACTA (Rosas), 2020 1.16 [0.73; 1.84] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Talaschian, 2021 1.25 [0.30; 5.14] 1.04[0.78; 1.38]COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021, Talaschian, 202130%1,132moderatenot evaluable clinical deteriorationdetailed resultsCORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20] 0.56[0.26; 1.20]CORIMUNO-TOCI-1 (Group 1), 202010%130NAnot evaluable clinical improvementdetailed resultsCOVACTA (Rosas), 2020 1.19 [0.81; 1.75] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15] 1.28[0.95; 1.72]COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, REMAP-CAP (tocilizumab), 2021362%1,440moderatenot evaluable clinical improvement (28-day)detailed resultsCOVACTA (Rosas), 2020 1.19 [0.81; 1.75] 1.19[0.81; 1.75]COVACTA (Rosas), 202010%438NAnot evaluable clinical improvement (time to event analysis only)detailed resultsLescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54] 1.09[0.87; 1.35]Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 202120%506moderatenot evaluable death or ventilationdetailed resultsCORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31] Rosas (REMDACTA), 2021 0.98 [0.72; 1.34] Veiga, 2021 1.54 [0.65; 3.63] 0.96[0.65; 1.43]CORIMUNO-TOCI-1 (Group 1), 2020, Rosas (REMDACTA), 2021, Veiga, 2021326%909moderatenot evaluable hospital dischargedetailed resultsMARIPOSA, 2021 0.88 [0.55; 1.40] Rosas (REMDACTA), 2021 0.97 [0.79; 1.20] 0.95[0.79; 1.16]MARIPOSA, 2021, Rosas (REMDACTA), 202120%649moderatenot evaluable mechanical ventilationdetailed resultsCOVACTA (Rosas), 2020 0.67 [0.39; 1.14] MARIPOSA, 2021 0.88 [0.37; 2.10] 0.72[0.46; 1.14]COVACTA (Rosas), 2020, MARIPOSA, 202120%370moderatenot evaluable ICU admissiondetailed resultsCOVACTA (Rosas), 2020 0.48 [0.25; 0.94] 0.48[0.25; 0.94]COVACTA (Rosas), 202010%191NAnot evaluable recoverydetailed resultsTalaschian, 2021 0.64 [0.14; 2.92] 0.64[0.14; 2.92]Talaschian, 202110%36NAnot evaluable serious adverse eventsdetailed resultsCOVACTA (Rosas), 2020 0.81 [0.54; 1.22] Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12] Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] Rosas (REMDACTA), 2021 0.83 [0.59; 1.18] Talaschian, 2021 7.93 [0.37; 171.38] Veiga, 2021 1.66 [0.60; 4.59] 0.99[0.77; 1.28]COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 2021616%1,747moderateserious adverse eventsdetailed resultsCOVACTA (Rosas), 2020 0.87 [0.52; 1.45] Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69] Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] Rosas (REMDACTA), 2021 1.32 [0.92; 1.89] Veiga, 2021 1.65 [0.81; 3.37] 1.18[0.95; 1.48]COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Veiga, 202150%1,711moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-05-09 22:47 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290